PL3634417T3 - Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem - Google Patents
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworemInfo
- Publication number
- PL3634417T3 PL3634417T3 PL18803171.0T PL18803171T PL3634417T3 PL 3634417 T3 PL3634417 T3 PL 3634417T3 PL 18803171 T PL18803171 T PL 18803171T PL 3634417 T3 PL3634417 T3 PL 3634417T3
- Authority
- PL
- Poland
- Prior art keywords
- quinazoline
- cancer
- treatment
- related disorders
- pyrazole derivatives
- Prior art date
Links
- ARMQQOXIHQRINP-UHFFFAOYSA-N 1H-pyrazole quinazoline Chemical class C=1C=NNC=1.N1=CN=CC2=CC=CC=C21 ARMQQOXIHQRINP-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507540P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/032868 WO2018213377A1 (en) | 2017-05-17 | 2018-05-16 | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3634417T3 true PL3634417T3 (pl) | 2023-09-25 |
Family
ID=64274816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18803171.0T PL3634417T3 (pl) | 2017-05-17 | 2018-05-16 | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11220492B2 (enExample) |
| EP (1) | EP3634417B1 (enExample) |
| JP (1) | JP7189155B2 (enExample) |
| CN (1) | CN110636846B (enExample) |
| ES (1) | ES2951809T3 (enExample) |
| PL (1) | PL3634417T3 (enExample) |
| WO (1) | WO2018213377A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| CA3179320A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112691107B (zh) * | 2021-02-03 | 2022-09-02 | 北京斯利安药业有限公司 | 一种药物组合物及其应用 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| CN113642386B (zh) * | 2021-07-02 | 2024-06-21 | 广州金域医学检验中心有限公司 | 基于深度学习评价鼻咽癌治疗效果的方法、装置、设备和介质 |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119139469B (zh) * | 2023-06-16 | 2026-07-24 | 武汉大学 | 腺苷受体抑制剂在制备用于治疗高脂血症与心脑血管疾病的药物中的应用 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026035034A1 (ko) * | 2024-08-06 | 2026-02-12 | 주식회사 대웅제약 | 신규한 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510362A (en) | 1992-03-13 | 1996-04-23 | Merck, Sharp And Dohme Limited | Imidazole, triazole and tetrazole derivatives |
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| BR0210149A (pt) | 2001-05-09 | 2004-06-29 | Newbiotics Inc | Pródrogas ativadas por deformilase de peptìdeo |
| US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
| EP1458708B1 (en) | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| MXPA04010550A (es) | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona. |
| US7354938B2 (en) * | 2004-03-23 | 2008-04-08 | Amgen Inc. | Pyrazole compounds and uses related thereto |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101384183B (zh) | 2005-02-04 | 2012-07-04 | 西诺米克斯公司 | 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用 |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2646333C (en) * | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| CN101511815A (zh) | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| US7994321B2 (en) | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US20110065633A1 (en) | 2008-01-30 | 2011-03-17 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| PE20091953A1 (es) | 2008-05-08 | 2010-01-09 | Du Pont | Azoles sustituidos como fungicidas |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011001872A (es) | 2008-08-18 | 2011-05-23 | Univ Yale | Moduladores de mif. |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| JP5643233B2 (ja) * | 2009-02-10 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8193235B2 (en) | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| US8993698B2 (en) | 2009-07-08 | 2015-03-31 | Isp Investments Inc. | 4- and 5 substituted 1,2,3-triazole moieties with at least one remote polymerizable moiety and polymers thereof |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| WO2011050284A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| US8748435B2 (en) * | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2013085890A1 (en) | 2011-12-06 | 2013-06-13 | Glaxo Group Limited | Therapeutic methods |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| DE102012102162A1 (de) | 2012-03-14 | 2013-09-19 | Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts | Ionenleitende polymere Verbindung für elektrochemische Zellen |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP3363434A1 (en) | 2013-03-14 | 2018-08-22 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| US9884806B2 (en) | 2013-08-30 | 2018-02-06 | Icahn School Of Medicine At Mount Sinai | Cyclic vinylogous amides as bromodomain inhibitors |
| EP2903044A1 (de) | 2014-02-04 | 2015-08-05 | cynora GmbH | Organische Moleküle zur Verwendung in optoelektronischen Bauelementen |
| WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| US20160251341A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted triazole compounds as serine protease inhibitors |
| EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| EP3618829B1 (en) | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
-
2018
- 2018-05-16 CN CN201880032987.1A patent/CN110636846B/zh active Active
- 2018-05-16 WO PCT/US2018/032868 patent/WO2018213377A1/en not_active Ceased
- 2018-05-16 JP JP2019563142A patent/JP7189155B2/ja active Active
- 2018-05-16 PL PL18803171.0T patent/PL3634417T3/pl unknown
- 2018-05-16 EP EP18803171.0A patent/EP3634417B1/en active Active
- 2018-05-16 ES ES18803171T patent/ES2951809T3/es active Active
- 2018-05-16 US US16/614,063 patent/US11220492B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020519664A (ja) | 2020-07-02 |
| EP3634417A1 (en) | 2020-04-15 |
| ES2951809T3 (es) | 2023-10-25 |
| CN110636846A (zh) | 2019-12-31 |
| CN110636846B (zh) | 2023-05-16 |
| US11220492B2 (en) | 2022-01-11 |
| US20210214346A1 (en) | 2021-07-15 |
| JP7189155B2 (ja) | 2022-12-13 |
| EP3634417C0 (en) | 2023-07-12 |
| WO2018213377A1 (en) | 2018-11-22 |
| EP3634417B1 (en) | 2023-07-12 |
| EP3634417A4 (en) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| EP3618829C0 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-ASSOCIATED DISORDERS | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| IL273835A (en) | Combined product for cancer treatment | |
| EP3371154A4 (en) | Heterocyclic derivatives and their use in the treatment of central nervous system disorders | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| HUE044665T2 (hu) | Fenilalanin-mentes fehérje PKU (fenilketonuria) kezelésére | |
| IL253642A0 (en) | Combined treatment for cancer | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1260601A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders |